A detailed history of Allworth Financial LP transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 1,290 shares of ALNY stock, worth $579,416. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,290
Previous 691 86.69%
Holding current value
$579,416
Previous $225,000 161.33%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Dec 02, 2025

BUY
$311.12 - $482.13 $186,360 - $288,795
599 Added 86.69%
1,290 $588,000
Q2 2025

Aug 07, 2025

BUY
$224.32 - $326.09 $16,375 - $23,804
73 Added 11.81%
691 $225,000
Q1 2025

Apr 30, 2025

BUY
$233.07 - $290.7 $4,894 - $6,104
21 Added 3.52%
618 $166,000
Q4 2024

Jan 30, 2025

BUY
$232.27 - $300.43 $8,826 - $11,416
38 Added 6.8%
597 $140,000
Q3 2024

Oct 23, 2024

SELL
$233.81 - $287.01 $1,402 - $1,722
-6 Reduced 1.06%
559 $153,000
Q2 2024

Jul 23, 2024

SELL
$143.31 - $247.0 $3,726 - $6,422
-26 Reduced 4.4%
565 $137,000
Q1 2024

Apr 25, 2024

BUY
$146.51 - $198.2 $50,692 - $68,577
346 Added 141.22%
591 $88,000
Q4 2023

Jan 24, 2024

SELL
$151.41 - $196.57 $2,422 - $3,145
-16 Reduced 6.13%
245 $46,000
Q3 2023

Oct 31, 2023

BUY
$170.77 - $211.65 $7,172 - $8,889
42 Added 19.18%
261 $46,000
Q2 2023

Jul 18, 2023

BUY
$185.01 - $212.05 $6,660 - $7,633
36 Added 19.67%
219 $41,000
Q1 2023

Apr 18, 2023

BUY
$182.66 - $235.53 $547 - $706
3 Added 1.67%
183 $36,000
Q4 2022

Jan 13, 2023

SELL
$185.53 - $241.31 $1,113 - $1,447
-6 Reduced 3.23%
180 $0
Q3 2022

Oct 18, 2022

BUY
$138.54 - $232.0 $22,582 - $37,816
163 Added 708.7%
186 $37,000
Q2 2022

Jul 13, 2022

BUY
$120.42 - $169.29 $963 - $1,354
8 Added 53.33%
23 $3,000
Q1 2022

Apr 22, 2022

SELL
$127.18 - $173.91 $5,850 - $7,999
-46 Reduced 75.41%
15 $2,000
Q4 2021

Jan 21, 2022

BUY
$159.56 - $209.29 $9,733 - $12,766
61 New
61 $10,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $55.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.